Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. is positioned favorably due to its robust technological capabilities, which are expected to enhance value-based care conversations and drive margin improvements through integration with recently acquired operations. The company's strong market share, alongside core trends in the pharmacy services sector, indicates an appealing earnings power potential, particularly from its newly acquired facilities. Additionally, the use of robotic dispensing technology, with approximately 80 machines currently in operation, has significantly improved accuracy and reduced the time to fill requests to less than one day, contributing to overall operational efficiency.

Bears say

Guardian Pharmacy Services Inc. faces a variety of significant risks that contribute to a negative outlook on its stock. These risks include potential changes in regulatory and reimbursement policies, challenges in managing relationships with long-term care facilities (LTCFs), and vulnerabilities related to supply chain disruptions. Furthermore, difficulties in hiring and retaining qualified clinical staff, sourcing and integrating acquisitions, and reliance on technology assets pose additional threats to the company’s operational stability and financial performance.

GRDN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 2 analysts, GRDN has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.